Actinogen Medical valuation analysis 2026

Actinogen Medical (ASX: ACW): XanaMIA probabilistic forecast and rNPV Verified Answer #1

Valuation date: August 13, 2026 Catalyst: XanaMIA Phase 2b/3 topline results expected in November 2026 Central risk-weighted expected value: A$0.086 per share Clinical-outcome probabilities: 24% Strong Success / 11% Moderate Success / 65% Futility Verified Answer #1

Important framing: This is a catalyst-specific, assumption-driven valuation—not investment advice. Verified Answer #1

XanaMIA is a small, binary late-stage biotechnology trial, and both the clinical probabilities and commercial valuation have unusually wide error bars. Verified Answer #1

Executive conclusion Verified Answer #1

My central estimate is a 24% probability that XanaMIA produces a Xanamem-favorable, nominally significant CDR-SB result at p<0.05, an 11% probability of a borderline p=0.05–0.10 result, and a 65% probability of p>0.10/futility. Verified Answer #1

The positive factors are prospective pTau181 enrichment, a prior favorable CDR-SB trend in a small high-pTau181 subgroup, central target engagement, a generally favorable safety record, and the January 2026 DMC non-futility decision. Verified Answer #1

The main negatives are that the supporting CDR-SB evidence comes from only 34 biomarker-high participants, the earlier trial did not show consistent benefit across the other major efficacy measures, pTau181 is principally a prognostic enrichment marker rather than proven evidence of treatment-specific responsiveness, and the 36-week primary endpoint remains highly sensitive to placebo-group decline and rater variance. Verified Answer #1

The DMC decision is modestly positive but not proof of efficacy: the efficacy boundary was not disclosed, only about 37% of the expected dataset was available, and the committee was not empowered to stop early for efficacy. (pmc.ncbi.nlm.nih.gov) Verified Answer #1

My scenario rNPVs are: Verified Answer #1

| November 2026 outcome | Probability | Conditional rNPV/share | EV contribution | |---|---:|---:|---:| | Bull: Strong Success, p<0.05 | 24% | A$0.312 | A$0.0749 | | Base: Moderate Success, p=0.05–0.10 | 11% | A$0.0616 | A$0.0068 | | Bear: Futility, p>0.10 | 65% | A$0.0059 | A$0.0038 | | Risk-weighted expected value | 100% | — | A$0.0855 ≈ A$0.086 | Verified Answer #1

The Bull and Base targets are already risk-adjusted for the probability of completing another pivotal trial and obtaining approval; the readout probabilities are then applied to those conditional scenario values. Verified Answer #1

This two-stage method avoids treating a positive November readout as equivalent to commercial approval. Verified Answer #1

Current clinical and financial position Verified Answer #1

XanaMIA is an active, no-longer-recruiting randomized study of 247 participants, comparing Xanamem 10 mg once daily with placebo for 36 weeks, followed by an open-label extension. Verified Answer #1

ClinicalTrials.gov lists the trial as Phase 2/3, with estimated primary completion in October 2026; Actinogen’s latest presentation schedules the last randomized-phase participant assessment for September and topline results for November 2026. (clinicaltrials.gov) Verified Answer #1

The trial enrolled mild-to-moderate Alzheimer’s patients selected for elevated plasma pTau181. Verified Answer #1

The primary endpoint is CDR-SB. Verified Answer #1

Actinogen has stated that the FDA’s September 2025 feedback and EMA’s May 2026 scientific advice support a development plan in which a positive XanaMIA study is followed by one additional pivotal placebo-controlled trial, together with ancillary clinical pharmacology, nonclinical, CMC and longer-term safety work. Verified Answer #1

This is company-reported regulatory alignment, not a binding commitment to approve the product or accept a future application. (investors.actinogen.com.au) Verified Answer #1

A July 29, 2026 management interview summarizing the June quarter reported A$16.7 million of cash and guidance that funding should extend beyond the November readout and into mid-2027. Verified Answer #1

I use A$15.0 million estimated cash at the August 13 valuation date, after allowing for post-quarter operating expenditure. Verified Answer #1

My starting basic share count is 3.66 billion, with scenario-specific future dilution added below. (finance.yahoo.com) Verified Answer #1

| Starting capitalization assumption | Amount | Treatment in model | |---|---:|---| | Reported June 30, 2026 cash | A$16.7m | Reference point | | Estimated cash at August 13, 2026 | A$15.0m | Added to rNPV | | Basic shares | 3.660bn | Starting denominator | | Existing options/warrants | Not valued separately | Exercise and dilution effects incorporated in scenario dilution factors | | Debt | No material separate deduction modeled | Funding and wind-down costs are incorporated by scenario | Verified Answer #1

Probability of Success matrix Verified Answer #1

2.1 Evidence used to set the prior Verified Answer #1

There is no robust, published industry database specifically measuring the success rate of pTau181-enriched, non-amyloid, oral Alzheimer’s trials using CDR-SB. Verified Answer #1

The forecast therefore bridges four different evidence sets rather than pretending a precise comparable-company base rate exists. Verified Answer #1

| Evidence | Interpretation for XanaMIA | PoS effect | |---|---|---:| | Historical Alzheimer’s Phase II/III development was exceptionally unsuccessful; one review identified roughly two approvals against 98 unique Phase II/III compound failures over 2004–2021. | Strong reason not to extrapolate small Phase 2 signals at face value. Verified Answer #1

Historical programs were, however, often less biomarker-selected than current trials. | Negative | | Modern AD trials increasingly use biomarkers; the 2026 pipeline review found biomarkers in 87% of active Phase 3 and 89% of active Phase 2 trials. | Biomarker selection is now close to standard practice, so pTau enrichment is helpful but not by itself a unique de-risking advantage. | Modestly positive | | In the prior XanADu biomarker analysis, the high-pTau181 subgroup had 34 participants. Verified Answer #1

Xanamem showed a 0.62-point favorable CDR-SB difference at 12 weeks, Cohen’s d≈0.41 and p=0.09. | Provides human efficacy evidence directly relevant to the current endpoint, dose and enrichment strategy. | Positive | | In the same analysis, benefit was not statistically demonstrated across the other major efficacy measures. | Raises regression-to-the-mean, endpoint-selection and small-subgroup concerns. | Negative | | High-pTau181 placebo patients worsened much faster than low-pTau181 patients on CDR-SB and ADCOMS. | Supports pTau181 as a prognostic enrichment tool capable of increasing endpoint movement. Verified Answer #1

It does not prove that pTau181 predicts responsiveness to 11β-HSD1 inhibition. | Positive for trial power, neutral for biological efficacy | | January 2026 DMC review of unblinded safety and efficacy-futility data recommended continuation without amendment. | Rules out at least some extreme-futility outcomes, but the boundary and treatment effect were not disclosed. | Modestly positive | | Trial is only 36 weeks, versus approximately 18 months in the pivotal lecanemab and donanemab trials. | Less time for disease trajectories to separate, although XanaMIA includes somewhat more advanced patients who may decline faster. | Negative/uncertain | Verified Answer #1

Historical attrition and current biomarker-use data are from the cited reviews; the Xanamem-specific numbers are from the peer-reviewed XanADu biomarker analysis. (pmc.ncbi.nlm.nih.gov) Verified Answer #1

2.2 Analyst PoS bridge Verified Answer #1

The following is an analyst judgment bridge, not a formally estimable Bayesian posterior. Verified Answer #1

Percentage-point adjustments are intended to show how the central 24% estimate was constructed and prevent the forecast from being an unexplained conclusion. Verified Answer #1

| PoS component | Strong-success adjustment | |---|---:| | Starting prior for a novel-mechanism, biomarker-selected Phase 2b/3 AD trial hitting its CDR-SB primary endpoint | 17% | | Prospective pTau181 enrichment and enrollment of patients expected to progress | +5 pp | | Prior favorable CDR-SB signal at the same 10 mg dose | +5 pp | | Demonstrated central target engagement and accumulated tolerability evidence | +2 pp | | January 2026 DMC non-futility continuation | +2 pp | | Small n=34 supporting subgroup, p=0.09 rather than p<0.05, and inconsistent supporting endpoints | −7 pp | | Central probability of p<0.05 in the favorable direction | 24% | Verified Answer #1

The 11% Moderate Success probability represents the mass expected in the relatively narrow nominal p=0.05–0.10 band under a mix of weak and near-threshold true effects. Verified Answer #1

The remaining 65% is assigned to p>0.10, including no effect, an effect too small for the trial to resolve, wrong-direction outcomes, and otherwise uninterpretable results. Verified Answer #1

2.3 PoS matrix Verified Answer #1

I assume that the quoted p-values are two-sided nominal primary-endpoint p-values in the Xanamem-favorable direction, with no undisclosed multiplicity penalty. Verified Answer #1

A significant result in the wrong direction would be classified as failure, not success. Verified Answer #1

| Outcome | CDR-SB definition | Central probability | Plausible analyst range | Likely interpretation | |---|---|---:|---:|---| | Strong Success | Favorable p<0.05 | 24% | 15–35% | Validates the enrichment strategy and makes XanaMIA potentially usable as one pivotal study. Verified Answer #1

Regulatory and partnering leverage rises materially, provided effect size, secondary endpoints and safety are coherent. | | Moderate Success | Favorable p=0.05–0.10 | 11% | 7–15% | Supports biological activity but normally does not establish a successful pivotal trial. Verified Answer #1

A larger, longer confirmatory trial and additional funding would be required. | | Futility | p>0.10, null or adverse direction | 65% | 50–78% | AD program is unlikely to proceed without an unusually compelling, prospectively defined subgroup or secondary-endpoint package. | | Total | — | 100% | — | — | Verified Answer #1

The ranges are judgmental sensitivity bounds, not statistical confidence intervals, and should not be summed across rows. Verified Answer #1

What would make a nominal p<0.05 result genuinely “strong”? Verified Answer #1

A p-value alone is insufficient. Verified Answer #1

The upper end of the Bull valuation requires all or most of the following: Verified Answer #1

A clinically interpretable CDR-SB difference, ideally at least approximately 0.45–0.60 points at 36 weeks, rather than significance produced by an unexpectedly small variance. Verified Answer #1

Directionally consistent ADCOMS, cognitive and activities-of-daily-living results. Verified Answer #1

No material imbalance in discontinuations, missing data or use of rescue/background therapies. Verified Answer #1

Broad benefit rather than dependence on a small post hoc subgroup. Verified Answer #1

Safety and tolerability sufficient for chronic oral use. Verified Answer #1

An effect that appears credible relative to placebo decline and baseline severity. Verified Answer #1

Milestone decision tree: November 2026–December 31, 2027 Verified Answer #1

3.1 Core regulatory point Verified Answer #1

Actinogen’s reported FDA and EMA feedback supports one additional pivotal trial after XanaMIA, but the readout still has to demonstrate that XanaMIA is sufficiently positive and well-conducted to form part of the eventual registrational package. Verified Answer #1

Scientific advice and meeting minutes reduce design uncertainty; they do not remove the agencies’ ability to request a larger population, longer duration, revised biomarker confirmation, additional safety exposure or different statistical analyses after seeing the data. (investors.actinogen.com.au) Verified Answer #1

I do not assume accelerated approval in the rNPV. Verified Answer #1

Unlike anti-amyloid antibodies, Xanamem currently lacks an established treatment-responsive surrogate reasonably likely to predict clinical benefit. Verified Answer #1

The model assumes traditional approval following another successful pivotal clinical trial. Verified Answer #1

3.2 Decision tree Verified Answer #1

| Timing | Strong Success: p<0.05 | Moderate Success: p=0.05–0.10 | Futility: p>0.10 | |---|---|---|---| | November 2026 | Release topline CDR-SB, safety and key secondaries. Verified Answer #1

Begin confirmatory analyses and partner data-room access. | Determine whether effect size is clinically credible despite missed significance. Verified Answer #1

Examine pre-specified subgroups and endpoint concordance. | Stop new AD spending pending full analysis. Verified Answer #1

Only continue if a prospectively defined subgroup and supportive endpoints provide an unusually strong rescue case. | | December 2026–January 2027 | Request FDA Type C/End-of-Phase-2 interaction and EMA follow-up scientific advice. Verified Answer #1

Initiate formal global-license or co-development process. | Seek FDA/EMA feedback before committing capital. Verified Answer #1

Begin bridge-financing and option-to-license discussions. | Implement cost reductions, preserve OLE data where useful, and assess MDD development, strategic alternatives or asset sale. | | Q1–Q2 2027 | Align on final pivotal trial: CDR-SB estimand, duration, sample size, biomarker confirmation, allowed anti-amyloid background therapy, multiplicity, missing-data handling, safety database and CMC package. | Regulators likely request a larger and/or longer study, with tighter biomarker confirmation and hierarchical secondary endpoints. | No routine AD Phase 3 meeting assumed. Verified Answer #1

Regulatory interaction would focus on whether any rescue analysis is sufficient to justify another trial. | | Q2–Q3 2027 | Target global partnership: material upfront payment, partner funding most of Phase 3, tiered royalties and milestones. | Most plausible deal is option-to-license, regional license or co-development with lower upfront and greater ACW co-funding. | Raise only enough capital for MDD/pipeline strategy or execute strategic transaction. Verified Answer #1

High dilution risk. | | Q3–Q4 2027 | Finalize protocol, manufacturing, CRO/site feasibility and regulatory submissions. Verified Answer #1

First-patient-in during Q4 2027 is feasible but aggressive. | Protocol may be finalized by year-end, but first-patient-in could slip into 2028 if financing or partnering is delayed. | AD program terminated or placed on indefinite hold; company value rests on cash, depression and corporate optionality. | | Status at December 31, 2027 | Partnered, protocol-aligned, and final pivotal trial initiated or ready to initiate. | Protocol broadly aligned but financing/partnering remains the gating event. | Restructured company with no material AD value in the model. | Verified Answer #1

3.3 Regulatory questions that must be resolved in 2027 Verified Answer #1

| Protocol issue | Why it matters | |---|---| | Trial duration | A 36-week signal may not be sufficient to demonstrate durable disease slowing. Verified Answer #1

My Phase 3 cost model assumes a 12–18-month final trial. | | Population and label | XanaMIA includes mild-to-moderate dementia, whereas approved anti-amyloid labels focus on MCI/mild dementia. Verified Answer #1

Regulators may favor a narrower or stratified population. | | pTau181 versus amyloid confirmation | Plasma pTau181 identifies likely progressive AD but may not have the same diagnostic specificity as an amyloid-PET/CSF-confirmed population. Verified Answer #1

The agencies may require orthogonal confirmation in at least a subset. | | Background anti-amyloid therapy | By 2027, excluding all antibody-treated patients could impair recruitment and commercial relevance; allowing them creates interaction, safety and statistical complexity. | | Primary estimand and missing data | Discontinuation, rescue treatment, death and institutionalization can materially affect CDR-SB interpretation. | | Secondary endpoint hierarchy | Supportive cognition, function and global measures will be important if the primary effect is modest. | | Safety exposure | A broadly used chronic oral drug will require an adequate long-term safety database. Verified Answer #1

The open-label extension helps but is uncontrolled. | | CMC/commercial formulation | Process validation, stability, drug substance sourcing and commercial-scale tablet manufacturing must be complete before filing. | Verified Answer #1

3.4 Potential licensing structures Verified Answer #1

The numbers below are valuation assumptions, not company guidance or claimed offers. Verified Answer #1

| Structure | Likely data threshold | Illustrative economics | Funding consequence | |---|---|---|---| | Global license — Bull model | Clear p<0.05, credible effect size, supportive secondaries and clean safety | US$100m upfront; US$450m additional development/regulatory/sales milestones; 18% average royalty; partner funds ~80% of remaining pivotal program | Phase 3 dilution limited mainly to existing options, working capital and negotiating timing. | | Option-to-license/co-development — Base model | p=0.05–0.10 or mixed endpoints but credible activity | US$50m upfront/option consideration; US$260m future milestones; 15% average royalty; partner funds ~50% | ACW needs a substantial bridge raise and retains meaningful Phase 3 cost exposure. | | Regional license | Positive result, but global partner unwilling to price full asset immediately | Ex-US or ex-US/EU rights licensed for cash and royalties; ACW retains a major market, potentially the US | More strategic upside but considerably greater financing and execution risk. | | Equity-linked strategic investment | Partner wants access without immediate full license | Premium equity investment plus Phase 3 funding option | Reduces near-term cash risk but can create dilution and partner-control complexity. | | M&A/asset acquisition | Very strong efficacy with competitive oral profile | Cash, shares and contingent-value rights | Removes standalone dilution but transaction probability is impossible to value reliably before data. | Verified Answer #1

Scenario-based rNPV Verified Answer #1

4.1 Methodology Verified Answer #1

The scenario value is calculated as: Verified Answer #1

[ \text{rNPV}_s = \frac{ \text{FX}\times\left[ \text{Conditional PoA}_s\times\text{After-tax royalty PV}_s +\text{Risk-adjusted milestone PV}_s \right] -\text{ACW residual development funding}_s +\text{net cash} }{\text{scenario diluted shares}} ] Verified Answer #1

where: Verified Answer #1

[ \text{After-tax royalty PV} = \text{Peak sales}\times\text{royalty rate}\times(1-25%\text{ tax}) \times\sum_t\frac{\text{sales ramp}_t}{(1+r)^t}. ] Verified Answer #1

The readout probabilities are then applied to the three conditional scenario values: Verified Answer #1

[ EV/share=0.24\times Bull+0.11\times Base+0.65\times Bear. ] Verified Answer #1

4.2 Common valuation assumptions Verified Answer #1

| Assumption | Bull | Base | Bear | |---|---:|---:|---:| | Valuation date | Aug. 13, 2026 | Aug. 13, 2026 | Aug. 13, 2026 | | Discount rate | 12.0% | 13.5% | 15.0% | | USD/AUD assumption | A$1 = US$0.65 | A$1 = US$0.65 | A$1 = US$0.65 | | Effective tax/withholding on royalty stream | 25% | 25% | N/A | | Commercial launch | 2031 | 2032 | No AD launch | | Conditional probability of approval after scenario occurs | 60% | 35% | 0% for AD | | Starting cash used in rNPV | A$15m | A$15m | Incorporated in residual value | | Basic shares | 3.660bn | 3.660bn | 3.660bn | | Modeled future dilution | 15% | 32% | 20% survival dilution | | Diluted share count | 4.209bn | 4.831bn | 4.392bn | | Terminal value | None | None | None | | Separate MDD value | Zero—to keep valuation AD-focused | Zero | A$30m residual option value | Verified Answer #1

Modeled sales ramp Verified Answer #1

| Commercial year | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | |---|---:|---:|---:|---:|---:|---:|---:|---:|---:|---:|---:|---:| | Sales as % of peak | 10% | 25% | 45% | 65% | 80% | 100% | 100% | 100% | 90% | 80% | 65% | 50% | Verified Answer #1

No value is assigned after Year 12, making the commercial model more conservative than a perpetual or terminal-multiple approach. Verified Answer #1

4.3 Peak sales assumptions by region Verified Answer #1

Peak sales are analyst estimates based on treated patients and assumed annual net pricing—not forecasts supplied by Actinogen. Verified Answer #1

| Region | Bull treated patients | Bull annual net price | Bull peak sales | Base treated patients | Base annual net price | Base peak sales | |---|---:|---:|---:|---:|---:|---:| | United States | 171,000 | US$12,000 | US$2.05bn | 96,000 | US$12,000 | US$1.15bn | | Europe | 100,000 | US$8,000 | US$0.80bn | 60,000 | US$8,000 | US$0.48bn | | Japan | 50,000 | US$7,000 | US$0.35bn | 24,000 | US$7,000 | US$0.17bn | | US/EU/JP peak sales | 321,000 | — | US$3.20bn | 180,000 | — | US$1.80bn | Verified Answer #1

The Bull case assumes a successful oral therapy is used both as an alternative to anti-amyloid antibodies and, following additional evidence, in some combination-treatment settings. Verified Answer #1

The Base case assumes a narrower label, slower reimbursement, lower physician conviction and significant antibody competition. Verified Answer #1

4.4 Phase 3 funding and dilution assumptions Verified Answer #1

| Funding item | Bull | Base | |---|---:|---:| | Estimated remaining pivotal/ancillary/CMC program cost | A$220m | A$260m | | Partner-funded proportion | 80% | 50% | | ACW gross share before upfront and other funding | A$44m | A$130m | | Upfront payment | US$100m | US$50m | | Net residual ACW development/operating funding deducted in rNPV | A$45m | A$70m | | Dilution factor | 15% | 32% | | Rationale | Strong data allow partner funding and option exercises at higher prices | Borderline data require bridge equity before or alongside a less favorable deal | Verified Answer #1

The gross program-cost assumptions include the final placebo-controlled trial, clinical pharmacology, long-term safety, CMC and pre-filing expenditure. Verified Answer #1

They are not company guidance. Verified Answer #1

4.5 Bull calculation: Strong Success Verified Answer #1

| Bull component | Calculation | Value | |---|---|---:| | Peak sales | US/EU/JP | US$3,200m | | Royalty rate | Average tiered royalty | 18% | | After-tax factor | 1 − 25% | 75% | | Discounted sales-ramp factor | 12-year ramp, 12% discount, launch 2031 | 2.374 | | Unrisked after-tax royalty PV | 3,200 × 18% × 75% × 2.374 | US$1,026m | | Conditional approval PoS | After strong November result | 60% | | Risk-adjusted royalty PV | 1,026 × 60% | US$615m | | Risk-adjusted milestone PV | Upfront plus individually risked future milestones | US$258m | | Total USD asset value | 615 + 258 | US$874m | | Converted to AUD | ÷ 0.65 | A$1,344m | | Less residual ACW funding | — | −A$45m | | Add current estimated cash | — | +A$15m | | Bull equity rNPV | — | A$1,314m | | Diluted shares | 3.660bn × 1.15 | 4.209bn | | Bull implied price | 1,314 ÷ 4,209 | A$0.312/share | Verified Answer #1

Bull milestone PV assumptions Verified Answer #1

| Milestone | Nominal amount | Timing from valuation | Probability within Bull case | |---|---:|---:|---:| | Global-license upfront | US$100m | 0.75 years | 100% | | Phase 3 initiation | US$50m | 1.5 years | 90% | | Phase 3 success | US$100m | 3.5 years | 65% | | Approval | US$150m | 4.5 years | 60% | | Sales milestones | US$150m | 7 years | 45% | | Discounted, risk-adjusted PV | US$550m nominal | — | US$258m PV | Verified Answer #1

4.6 Base calculation: Moderate Success Verified Answer #1

| Base component | Calculation | Value | |---|---|---:| | Peak sales | US/EU/JP | US$1,800m | | Royalty rate | Average tiered royalty | 15% | | After-tax factor | 1 − 25% | 75% | | Discounted sales-ramp factor | 12-year ramp, 13.5% discount, launch 2032 | 1.822 | | Unrisked after-tax royalty PV | 1,800 × 15% × 75% × 1.822 | US$369m | | Conditional approval PoS | After moderate November result | 35% | | Risk-adjusted royalty PV | 369 × 35% | US$129m | | Risk-adjusted milestone PV | Upfront plus individually risked future milestones | US$100m | | Total USD asset value | 129 + 100 | US$229m | | Converted to AUD | ÷ 0.65 | A$352m | | Less residual ACW funding | — | −A$70m | | Add current estimated cash | — | +A$15m | | Base equity rNPV | — | A$297m | | Diluted shares | 3.660bn × 1.32 | 4.831bn | | Base implied price | 297 ÷ 4,831 | A$0.0616/share | Verified Answer #1

Base milestone PV assumptions Verified Answer #1

| Milestone | Nominal amount | Timing | Probability within Base case | |---|---:|---:|---:| | Upfront/option payment | US$50m | 1 year | 100% | | Phase 3 initiation | US$25m | 1.75 years | 80% | | Phase 3 success | US$60m | 4 years | 40% | | Approval | US$100m | 5 years | 35% | | Sales milestones | US$75m | 8 years | 25% | | Discounted, risk-adjusted PV | US$310m nominal | — | US$100m PV | Verified Answer #1

4.7 Bear calculation: Futility Verified Answer #1

The Bear case assigns zero value to the Alzheimer’s indication. Verified Answer #1

It preserves only a small option value for depression and other strategic alternatives. Verified Answer #1

Xanamem’s Phase 2 depression results were published in the British Journal of Psychiatry in July 2026, but a separate depression-development valuation is outside the scope of this AD-focused analysis. (globenewswire.com) Verified Answer #1

| Bear component | Value | |---|---:| | Residual MDD/pipeline option | A$30m | | Cash remaining after readout and restructuring | A$6m | | Wind-down, liabilities and corporate costs | −A$10m | | Bear equity value | A$26m | | Diluted shares after survival financing | 4.392bn | | Bear implied price | A$0.0059/share | Verified Answer #1

Risk-weighted expected value Verified Answer #1

| Scenario | Probability | Price target | Weighted contribution | |---|---:|---:|---:| | Bull | 24% | A$0.3122 | A$0.0749 | | Base | 11% | A$0.0616 | A$0.0068 | | Bear | 65% | A$0.0059 | A$0.0038 | | Expected value | 100% | — | A$0.0855 | Verified Answer #1

Central risk-weighted EV Verified Answer #1

[ (24%\times A$0.3122)+(11%\times A$0.0616)+(65%\times A$0.0059) =\boxed{A$0.0855} ] Verified Answer #1

Rounded EV: A$0.086 per share Verified Answer #1

A reasonable broad sensitivity range is approximately A$0.057–A$0.121 per share. Verified Answer #1

The lower end assumes roughly 15% Strong Success probability and greater futility weight; the upper end assumes roughly 35% Strong Success and better conversion of strong data into a partner-funded pivotal program. Verified Answer #1

This is a scenario range, not a confidence interval. Verified Answer #1

Placebo response and CDR-SB risk Verified Answer #1

6.1 The relevant placebo risk is low decline, not conventional symptomatic response Verified Answer #1

In a disease-progression trial, the main problem is usually not that placebo patients improve dramatically. Verified Answer #1

It is that they decline less than expected, reducing the absolute drug-placebo difference. Verified Answer #1

Elevated pTau181 appears to select faster decliners: in the prior high-pTau181 XanADu subgroup, the placebo arm worsened by approximately 0.98 CDR-SB points over only 12 weeks, although that estimate came from only 18 placebo patients and should not be extrapolated linearly to XanaMIA. (pmc.ncbi.nlm.nih.gov) Verified Answer #1

6.2 Quantitative placebo sensitivity Verified Answer #1

The following power illustration assumes: Verified Answer #1

247 randomized participants; Verified Answer #1

approximately 210 effective evaluable participants after missing data, or 105 per arm; Verified Answer #1

CDR-SB change-score standard deviation of 1.8; Verified Answer #1

standard error of the difference: Verified Answer #1

[ SE=1.8\sqrt{\frac{1}{105}+\frac{1}{105}}\approx0.248; ] Verified Answer #1

Xanamem produces a constant 30% relative slowing of placebo decline. Verified Answer #1

These are model assumptions, not unblinded XanaMIA data. Verified Answer #1

| Mean placebo worsening at 36 weeks | 30% slowing gives treatment difference | Approx. z-score | Approx. two-sided p-value | Outcome band | |---:|---:|---:|---:|---| | 0.8 CDR-SB points | 0.24 | 0.97 | 0.33 | Futility | | 1.2 points | 0.36 | 1.45 | 0.15 | Futility | | 1.5 points | 0.45 | 1.81 | 0.07 | Moderate Success | | 2.0 points | 0.60 | 2.42 | 0.016 | Strong Success | Verified Answer #1

Interpretation Verified Answer #1

The same biological 30% relative treatment effect could generate anything from p≈0.33 to p≈0.016 depending on the placebo trajectory. Verified Answer #1

This is why pTau181 enrichment matters: it is intended to increase measurable decline. Verified Answer #1

But enrichment only helps if the population remains sufficiently homogeneous and the CDR-SB measurement variance is controlled. Verified Answer #1

The key November variables will therefore be: Verified Answer #1

actual placebo decline; Verified Answer #1

standard deviation and site-to-site variance; Verified Answer #1

missing-data rate and reasons for discontinuation; Verified Answer #1

whether the treatment effect is constant across baseline severity; Verified Answer #1

whether US and Australian sites produce compatible results; Verified Answer #1

whether secondary endpoints support the primary finding. Verified Answer #1

Competitive pressure from anti-amyloid antibodies Verified Answer #1

Lecanemab and donanemab have established the present efficacy and regulatory benchmark. Verified Answer #1

Donanemab’s pivotal study showed a 0.70-point CDR-SB difference, corresponding to 29% slowing at 76 weeks. Verified Answer #1

Lecanemab’s label is based on a statistically significant clinical benefit in early AD and requires amyloid confirmation plus baseline and serial MRI surveillance. Verified Answer #1

Both products carry ARIA warnings. (fda.gov) Verified Answer #1

In Europe, both Leqembi and Kisunla are authorized for early Alzheimer’s disease in patients with one or no ApoE4 copy, with controlled-access and ARIA-monitoring requirements. Verified Answer #1

Kisunla is administered every four weeks and its EU treatment duration is capped at 18 months; Leqembi’s current US label includes IV treatment and, after 18 months, IV-monthly or weekly subcutaneous maintenance options. Verified Answer #1

The availability of subcutaneous lecanemab maintenance partially narrows—but does not eliminate—the convenience advantage of a daily pill. (ema.europa.eu) Verified Answer #1

| Competitive dimension | Anti-amyloid position | Potential Xanamem position | Valuation implication | |---|---|---|---| | Demonstrated efficacy | Proven statistically significant slowing in large Phase 3 trials | Not yet demonstrated in a prospectively selected pivotal dataset | The November efficacy effect size is the primary determinant of value. | | Administration | Infusion induction; lecanemab has later subcutaneous maintenance | Once-daily oral tablet | Major advantage if adherence and tolerability are acceptable. | | Monitoring | Amyloid confirmation, ApoE testing and serial MRI, ARIA management | Could have substantially lower monitoring burden if the safety profile remains clean | Supports lower total treatment cost and wider community use. Verified Answer #1

This is not yet an approved-label fact. | | Eligible disease stage | MCI or mild dementia in current labels | XanaMIA includes mild-to-moderate dementia | Potentially broader segment, but regulators may narrow the eventual label. | | Mechanism | Removes amyloid | Reduces intracellular brain cortisol production through 11β-HSD1 inhibition | Could support alternative or combination use rather than direct displacement. | | Combination opportunity | Amyloid backbone therapy | Mechanistically complementary | Commercial upside, but dedicated interaction and combination evidence would be required. | | Physician familiarity | Growing experience and infrastructure | Novel mechanism with limited late-stage evidence | Slower initial uptake unless XanaMIA and Phase 3 results are highly persuasive. | | Pricing | High-cost biologic plus infusion/MRI infrastructure | Model assumes US net price of US$12,000 annually | Lower pricing can broaden access but limits revenue per patient. | Verified Answer #1

Competitive conclusions Verified Answer #1

Positive for Xanamem Verified Answer #1

A genuinely effective daily oral drug could reach patients who are unsuitable for, unwilling to receive or unable to access antibody therapy. Verified Answer #1

A lack of class-specific ARIA monitoring would be commercially important if confirmed in a larger safety database. Verified Answer #1

A mild-to-moderate label could extend beyond the current antibody population. Verified Answer #1

Different biology creates a plausible future combination strategy. Verified Answer #1

Negative for Xanamem Verified Answer #1

By the time Xanamem could launch, anti-amyloid diagnosis, infusion and monitoring infrastructure will be more mature. Verified Answer #1

Xanamem must compete against products with large randomized Phase 3 datasets and regulatory validation. Verified Answer #1

Subcutaneous antibody maintenance reduces the convenience gap. Verified Answer #1

A small 36-week CDR-SB benefit may be viewed as less convincing than an 18-month antibody result, even if the nominal p-value is significant. Verified Answer #1

Payers may require amyloid confirmation or restrict use to patients who fail or cannot use antibodies unless Xanamem shows a clearly differentiated efficacy/safety profile. Verified Answer #1

A direct cross-trial numerical comparison would be inappropriate because XanaMIA differs in duration, severity, biomarker selection and sample size. Verified Answer #1

Nonetheless, an absolute placebo-adjusted benefit below approximately 0.3 points at 36 weeks would probably be commercially difficult, while a result around 0.5–0.7 points with supporting secondaries would support a materially differentiated oral profile. Verified Answer #1

Principal risks to the valuation Verified Answer #1

| Risk | Probability/importance | Mechanism of value loss | Potential mitigation | |---|---|---|---| | Low placebo decline | Very high | Reduces absolute CDR-SB separation and pushes a biologically active drug into p>0.10 | pTau181 enrichment, inclusion of progressive patients, rater standardization | | CDR-SB variance/rater noise | High | Increases standard error and makes p-value unstable in a 247-person trial | Central training, site monitoring, sensitivity analyses | | Prior-subgroup regression to mean | High | The n=34, p=0.09 signal may not reproduce prospectively | XanaMIA is the required replication test | | Endpoint discordance | High | Significant CDR-SB with neutral cognition/function may reduce regulatory and partner confidence | Coherent secondary endpoint package | | Insufficient duration | Medium-high | A 36-week difference may be viewed as transient or not durable | OLE data and longer final pivotal trial | | Regulatory design changes | Medium | FDA/EMA can request larger sample, longer trial, different biomarker confirmation or more safety data | Early 2027 parallel meetings and protocol harmonization | | Financing/dilution | High | Even positive data may require A$70m-plus residual company funding if partnering terms disappoint | Global license, regional deal, strategic equity investment, option exercise | | Anti-amyloid competition | High | Restricts first-line share and creates a higher evidence bar | Oral use, broader-stage label, lower monitoring burden, combination development | | Safety signal in larger exposure | Medium | Chronic broad-use opportunity depends on benign safety and tolerability | OLE and larger controlled safety database | | Partner timing | Medium-high | Delay between positive data and deal signing could force a discounted bridge raise | Prepare data room and regulatory package before topline data | | FX risk | Medium | Most asset cash flows are modeled in USD but equity is valued in AUD | At A$1=US$0.65; ±10% FX changes the asset portion of targets by roughly ±10% | Verified Answer #1

Final assessment Verified Answer #1

XanaMIA is better designed than the historical unselected Alzheimer’s trial: it prospectively enrolls pTau181-positive patients expected to decline, uses an accepted clinical endpoint, evaluates the same dose associated with the earlier favorable CDR-SB trend, and has passed a confidential non-futility review. Verified Answer #1

But those factors do not convert a fragile n=34 subgroup result into a high-probability pivotal success. Verified Answer #1

My central forecast is therefore deliberately below 50% for any positive p≤0.10 result: Verified Answer #1

Strong Success: 24% Verified Answer #1

Moderate Success: 11% Verified Answer #1

Futility: 65% Verified Answer #1

The asymmetric payoff arises because a clean p<0.05 result could convert Xanamem into a partnerable, potentially multi-billion-dollar peak-sales oral Alzheimer’s asset. Verified Answer #1

Conversely, p>0.10 would remove most of ACW’s Alzheimer’s value and leave only cash, depression optionality and strategic value. Verified Answer #1

Price-target summary Verified Answer #1

| Metric | Value | |---|---:| | Bull target | A$0.312/share | | Base target | A$0.0616/share | | Bear target | A$0.0059/share | | Risk-weighted EV | A$0.0855/share | | Rounded central EV | A$0.086/share | | Broad PoS/valuation sensitivity range | A$0.057–A$0.121/share | Verified Answer #1

The most important November disclosure will not be the headline p-value alone. Verified Answer #1

Investors should scrutinize the absolute CDR-SB difference, placebo decline, confidence interval, secondary-endpoint consistency, missing-data pattern, site/geography interaction and safety profile. Verified Answer #1

Those elements will determine whether the appropriate post-readout value is near the upper Bull estimate, the lower portion of the Bull range, or merely the Base case. Verified Answer #1

Key sources Verified Answer #1

Actinogen Medical. (2026, July). Senior-management/corporate presentation: XanaMIA status, DMC reviews, regulatory pathway and November 2026 catalyst. (investors.actinogen.com.au) Verified Answer #1

ClinicalTrials.gov. (Updated April 23, 2026). NCT06125951: Effect of 10 mg Xanamem on dementia due to Alzheimer’s disease. (clinicaltrials.gov) Verified Answer #1

Actinogen Medical. (2026, January 30). Positive XanaMIA interim-analysis recommendation. (investors.actinogen.com.au) Verified Answer #1

Taylor, J., et al. (2024). Plasma pTau181 predicts clinical progression in a Phase 2 randomized controlled trial of the 11β-HSD1 inhibitor Xanamem for mild Alzheimer’s disease. Journal of Alzheimer’s Disease. (pmc.ncbi.nlm.nih.gov) Verified Answer #1

Cummings, J., et al. (2022). Alzheimer’s disease: Key insights from two decades of clinical-trial failures. (pmc.ncbi.nlm.nih.gov) Verified Answer #1

Cummings, J., et al. (2026). Alzheimer’s disease drug-development pipeline: 2026. (pmc.ncbi.nlm.nih.gov) Verified Answer #1

U.S. Verified Answer #1

Food and Drug Administration. Leqembi prescribing information; Kisunla Drug Trials Snapshot. (accessdata.fda.gov) Verified Answer #1

European Medicines Agency. Leqembi and Kisunla European public assessment information. (ema.europa.eu) Verified Answer #1

Sources: [1] Plasma pTau181 Predicts Clinical Progression in a Phase 2 Randomized Controlled Trial of the 11β-HSD1 Inhibitor Xanamem® for Mild Alzheimer’s Disease - PMC [2] Study Details | NCT06125951 | Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease | ClinicalTrials.gov [3] ASX:ACW - ACW September 2025 quarterly activity report & Appendix 4C [4] Actinogen Medical targets November XanaMIA results highlighting strong June quarter [5] Alzheimer’s Disease: Key Insights from Two Decades of Clinical Trial Failures - PMC [6] Xanamem proof-of-concept trial demonstrating [7] Drug Trials Snapshots: KISUNLA | FDA [8] EMA/544423/2024 [9] https://investors.actinogen.com.au/announcements/7622474 [10] https://clinicaltrials.gov/study/NCT06125951 [11] https://investors.actinogen.com.au/announcements/7333137 [12] https://pmc.ncbi.nlm.nih.gov/articles/PMC11307031/ [13] https://pmc.ncbi.nlm.nih.gov/articles/PMC9198803/ [14] https://pmc.ncbi.nlm.nih.gov/articles/PMC13140253/ [15] https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761269s012s015lbl.pdf [16] https://www.ema.europa.eu/en/documents/overview/leqembi-epar-medicine-overview_en.pdf Verified Answer #1